Opdualag
Opdualag ingredients
| Active ingredient | Strength |
|---|---|
| Nivolumab | 12 mg/mL |
| Relatlimab | 4 mg/mL |
What Opdualag is used for
The FDA lists the approved uses on the official label (below). In the EU, nivolumab is approved as Opdivo for:
Melanoma Opdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older.Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1). Adjuvant treatment of melanoma Opdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection (see section 5.1). Non-small cell lung cancer (NSCLC) Opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line tre…
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Opdualag
- Generic name
- Nivolumab and relatlimab-rmbw
- Made by
- E.R. Squibb & Sons, L.L.C.
- Forms
- Injection
- Given
- Intravenous
- Drug class
- Lymphocyte Activation Gene-3 Blocker, Programmed Death Receptor-1 Blocking Antibody
- FDA approval
- Biologic licence (BLA) BLA761234
- On the US market since
- 2022
Official information
- Opdualag prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Nivolumab and relatlimab-rmbw)
In India
- Nivolumab: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Opdualag?
Opdualag (Nivolumab and relatlimab-rmbw) is a cancer medicine made by E.R. Squibb & Sons, L.L.C., approved by the US FDA.
What are the ingredients of Opdualag?
Opdualag contains Nivolumab (12 mg/mL); Relatlimab (4 mg/mL).
Is Opdualag approved in Europe?
The same active substance is approved in the EU as Opdivo, Opdualag.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA